enGene Therapeutics ENGN
NASDAQ ENGN
$2.41 +0.13 (+5.70%)
At close: Nov 13, 2026 · 4:00 PM EST

enGene Therapeutics (ENGN) Convertible Debt (2022)

Updated

enGene Therapeutics' Convertible Debt was $17.41 million in fiscal Q4 2022 (quarter ended Oct 31, 2022).

Analysis

enGene Therapeutics (ENGN) Convertible Debt (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn
5 Novartis Ag 306.35 Bn 279.93 Bn -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn
10 enGene Therapeutics 161.50 Mn -832.97 Mn -
Historic Data

Historic Data

Download Data
DateValue
Oct 31, 2022 17.41 Mn
API Access

enGene Therapeutics Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=ENGN&period=max&api_key=YOUR_API_KEY